Astraea Therapeutics is a discovery-stage biopharmaceutical company, focused on the discovery and preclinical development of small-molecule therapeutics for the treatment of drug addiction and central nervous system disorders including pain and neurodegenerative diseases. Astraeas core competencies in innovative drug discovery are anchored in long-standing expertise in novel target validation, creation of new molecular entities and intellectual property, well-defined translational development, and a mission to develop life-changing medications for unmet needs in CNS disorders. ? ?Astraeas medication discovery focuses on two novel pharmacological targets, having the potential to deliver transformative treatments for the opioid crisis, chronic pain therapy, and smoking cessation relapse.
